Regen Biopharma Inc (RGBP) 0.0880 $RGBP
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
PR Newswire - Thu Jun 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
PR Newswire - Tue Jun 07, 6:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen's NR2F6 tCellVax and small molecule programs.
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
PR Newswire - Thu Jun 02, 6:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a "checkpoint inhibitor pill." Previously, the Company reported the use of gene silencing of NR2F6 leads to:
Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
PR Newswire - Wed Jun 01, 8:23AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has been approved by OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace with an effective trading date of May 31, 2016. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
PR Newswire - Tue May 24, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) has applied to OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
PR Newswire - Thu May 19, 6:00AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a preclinical development program aimed at creating the first cord blood based cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. In a provisional patent application, Regen described a generation of cord blood derived killer cells whose anti-cancer activity was potentiated by gene silencing. The product in development will be a "universal donor" cellular immunotherapy, which can be shipped frozen to the site of use and does not involve complex cellular manipulations by the treating institution.
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
PR Newswire - Wed May 11, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) announced today that potential market expansion of its HemaXellerate therapy for aplastic anemia is a strategic priority.
Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study
PR Newswire - Thu Apr 28, 6:00AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) has entered into a non-exclusive license agreement with Pan Am Cancer Treatment Center in Tijuana, Mexico to test HemaXellerate in a first-in-human proof of concept study. Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with HemaXellerate, and outcomes will be measured at one, three and six months. This study was initiated by Dr. Julio Selva Pallares, Professor of Clinical Hematology at the Autonomous University of Baja California and Director of its hematology transfusion unit.
Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
PR Newswire - Thu Apr 21, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
PR Newswire - Wed Mar 23, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer (immunotherapy).
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
PR Newswire - Wed Feb 03, 7:30AM CST
Regen BioPharma, Inc. , (OTCBB: RGBP) and (PINK: RGBP) announced the filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 149.62 (-2.68), ATRA: 19.85 (-0.85), STML: 7.00 (-0.20), SNTA: 0.34 (+0.02), ATNM: 1.80 (-0.01), SNDX: 12.32 (-0.29), BLCM: 12.18 (-0.56), BPTH: 1.96 (-0.11), TEVA: 52.01 (-0.20), AGIO: 47.48 (-1.34), XLRN: 34.38 (-1.92), ARRY: 3.25 (-0.01)
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
PR Newswire - Tue Jan 26, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the Food and Drug Administration (FDA) of an application requesting Orphan Drug status for the use of HemaXellerate for the treatment of aplastic anemia.
Regen BioPharma signs formal cancer research collaboration agreement with National Institutes of Health
M2 - Thu Jan 21, 5:40AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) reported on Wednesday that it has entered into a formal cancer research collaboration agreement to jointly explore the biology of the NR2F6 protein with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
Regen BioPharma President Harry Lander Provides Open Letter to Shareholders on Company's Progress and Developments
PR Newswire - Wed Jan 13, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) provided the following update for its shareholders:
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 82.09 (-1.03)
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
PR Newswire - Thu Jun 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
PR Newswire - Tue Jun 07, 6:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen's NR2F6 tCellVax and small molecule programs.
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
PR Newswire - Thu Jun 02, 6:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a "checkpoint inhibitor pill." Previously, the Company reported the use of gene silencing of NR2F6 leads to:
Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
PR Newswire - Wed Jun 01, 8:23AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has been approved by OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace with an effective trading date of May 31, 2016. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
PR Newswire - Tue May 24, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) has applied to OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
PR Newswire - Thu May 19, 6:00AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a preclinical development program aimed at creating the first cord blood based cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. In a provisional patent application, Regen described a generation of cord blood derived killer cells whose anti-cancer activity was potentiated by gene silencing. The product in development will be a "universal donor" cellular immunotherapy, which can be shipped frozen to the site of use and does not involve complex cellular manipulations by the treating institution.
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
PR Newswire - Wed May 11, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) announced today that potential market expansion of its HemaXellerate therapy for aplastic anemia is a strategic priority.
Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study
PR Newswire - Thu Apr 28, 6:00AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) has entered into a non-exclusive license agreement with Pan Am Cancer Treatment Center in Tijuana, Mexico to test HemaXellerate in a first-in-human proof of concept study. Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with HemaXellerate, and outcomes will be measured at one, three and six months. This study was initiated by Dr. Julio Selva Pallares, Professor of Clinical Hematology at the Autonomous University of Baja California and Director of its hematology transfusion unit.
Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
PR Newswire - Thu Apr 21, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
PR Newswire - Wed Mar 23, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer (immunotherapy).
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
PR Newswire - Wed Feb 03, 7:30AM CST
Regen BioPharma, Inc. , (OTCBB: RGBP) and (PINK: RGBP) announced the filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 149.62 (-2.68), ATRA: 19.85 (-0.85), STML: 7.00 (-0.20), SNTA: 0.34 (+0.02), ATNM: 1.80 (-0.01), SNDX: 12.32 (-0.29), BLCM: 12.18 (-0.56), BPTH: 1.96 (-0.11), TEVA: 52.01 (-0.20), AGIO: 47.48 (-1.34), XLRN: 34.38 (-1.92), ARRY: 3.25 (-0.01)
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
PR Newswire - Tue Jan 26, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the Food and Drug Administration (FDA) of an application requesting Orphan Drug status for the use of HemaXellerate for the treatment of aplastic anemia.
Regen BioPharma signs formal cancer research collaboration agreement with National Institutes of Health
M2 - Thu Jan 21, 5:40AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) reported on Wednesday that it has entered into a formal cancer research collaboration agreement to jointly explore the biology of the NR2F6 protein with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
Regen BioPharma President Harry Lander Provides Open Letter to Shareholders on Company's Progress and Developments
PR Newswire - Wed Jan 13, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) provided the following update for its shareholders:
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 82.09 (-1.03)
